3CHIARLE R, PODDA A, PROLLA G, et al. CD30 in normal and neoplastic cells[J]. Clin Immunol, 1999, 90(2) : 157 -164.
4FRANCISCO J A, CERVENY C G, MEYER D L, et al. cAC10 - vcMMAE, an anti -CD30 -monomethyl auristatin E conjugate with potent and selective antitumor activity[ J]. Blood, 2003, 102 (4) : 1458 - 1465.
5OKELEY N M, MIYAMOTO J B, ZHANG X, et al. Intracellular activation of SGN - 35, a potent anti - CD30 antibody - drug con- jugate[J]. Clin Cancer Res, 2010, 16(3): 888 -897.
6SENTER P D. Potent antibody drug conjugates for cancer therapy [J]. Curr Opin Chem Biol, 2009, 13(3) : 235 -244.
7YOUNES A, BARTLETT N L, LEONARD J P, et al. Brentux- imab vedotin ( SGN - 35 ) for relapsed CD30 - positive lymphomas [J]. NEnglJMed, 2010, 363(19): 1812-1821.
8KATZ J, JANIK J E, YOUNES A. Brentuximab Vedotin ( SGN - 35) [J]. Clin Cancer Res, 2011, 17(20): 6428 -6436.
9FANALE M, BARTLETT N L, FORERO TORRES A, et al. The antibody - drug conjugate brentuximab vedotin ( SGN - 35 ) in- duced multiple objective responses in patients with relapsed or re- fractory CD30 - positive lymphomas in a phase 1 weekly dosing study. ASH Annual Meeting Abstracts [ J]. Blood, 2009, 114 (22) : 2731.
10ANSELMO A P, CAVALIERI E, OSTI F M, et al. Intermediate stage Hodgkin's disease: preliminary results on 210 patients trea- ted with four ABVD chemotherapy cycles plus extended versus in- volved field radiotherapy [ J ]. Anticancer Res, 2004, 24 ( 6 ) : 4045 - 4050.
